2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2012
Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]
Brust J, Shah N, Scott M, Chaiyachati K, Lygizos M, van der Merwe T, Bamber S, Radebe Z, Loveday M, Moll A, Margot B, Lalloo U, Friedland G, Gandhi N. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 998-1004. PMID: 22668560, PMCID: PMC3390442, DOI: 10.5588/ijtld.11.0713.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAnti-HIV AgentsAntitubercular AgentsAttitude of Health PersonnelCaregiversCD4 Lymphocyte CountCoinfectionDelivery of Health Care, IntegratedFeasibility StudiesFemaleHealth Knowledge, Attitudes, PracticeHIV InfectionsHome Care ServicesHumansMaleMedication AdherenceOrganizational ObjectivesPatient Care TeamProgram DevelopmentProgram EvaluationRural Health ServicesSocial SupportSouth AfricaTime FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantViral LoadConceptsMultidrug-resistant tuberculosisHome-based treatmentHIV treatmentAdverse reactionsTreatment outcomesTreatment programHigh HIV prevalent settingsMDR-TB treatmentEscalation of careSevere adverse eventsHIV treatment programsHIV-prevalent settingsCommunity health workersCo-infection ratePatient treatment programTreatment modelPromising treatment modelNew treatment modelRural KwaZulu-NatalHIV-coMonthly culturesAdherence supportAdverse eventsClinical responseHIV outcomesRisk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2011
Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting
Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, Maluleke M, Mhlope H, Margot B, Friedland G, Shah N, Gandhi N. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2011, 15: 1170-1175. PMID: 21943840, DOI: 10.5588/ijtld.10.0781.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntitubercular AgentsExtensively Drug-Resistant TuberculosisFamily CharacteristicsFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleMicrobial Sensitivity TestsMiddle AgedPrevalenceProspective StudiesSouth AfricaTime FactorsTuberculosis, Multidrug-ResistantYoung AdultConceptsDrug-resistant tuberculosisHousehold contactsXDR-TBIndex caseMDR-TBPrevalence settingsHigh human immunodeficiency virus (HIV) prevalence settingsMDR-TB index casesHigh HIV prevalence settingsAdult household contactsHousehold contact investigationIndex case diagnosisMost secondary casesHIV prevalence settingsRate of MDRDrug susceptibility testingDiagnosis of MDRPublic health activitiesActive tuberculosisNosocomial transmissionContact investigationMedian timeIncidence rateSecondary casesObservational studyCulture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa
Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLOS ONE 2011, 6: e15841. PMID: 21253585, PMCID: PMC3017058, DOI: 10.1371/journal.pone.0015841.Peer-Reviewed Original ResearchConceptsMDR-TB patientsCulture conversion rateMDR-TB treatmentMonths of therapyAntiretroviral therapyHIV-coCulture conversionHIV co-infected patientsMultidrug-resistant tuberculosis patientsTiming of ARTMDR-TB therapyCo-infected patientsHIV-negative patientsSecond-line regimenSimilar cure ratesDays of initiationResource-limited settingsHIV prevalentART medicationsCD4 countMDR-TBTuberculosis patientsSputum cultureSuch patientsHIV status
2005
Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence
Mannheimer S, Matts J, Telzak E, Chesney M, Child C, Wu A, Friedland G, Aids F. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005, 17: 10-22. PMID: 15832830, DOI: 10.1080/09540120412331305098.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherenceQOL scoresQuality of lifeTerry Beirn Community ProgramsNewer ART regimensSummary QoL scoresCells/mm3Mean QOL scoreAntiretroviral clinical trialsHigher QoL scoresBaseline CD4ART regimensART-naïveHIV populationMean agePoor adherenceSF-12Clinical trialsImproved QoLClinical researchQoLAdherenceMonthsHIV
2001
Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition
McCance‐Katz E, Rainey P, Friedland G, Kosten T, Jatlow P. Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. American Journal On Addictions 2001, 10: 296-307. PMID: 11783744, DOI: 10.1111/j.1521-0391.2001.tb00519.x.Peer-Reviewed Original ResearchConceptsOpioid-dependence pharmacotherapyHuman immunodeficiency virusZDV toxicityActive antiretroviral therapyInjection drug usersTime-concentration curveZDV pharmacokineticsZidovudine dispositionAntiretroviral therapyOpioid pharmacotherapyDose adjustmentOpioid dependenceImmunodeficiency virusZDV concentrationsControl subjectsMethadone maintenanceDrug usersPharmacotherapyZidovudineBuprenorphineNaltrexoneSignificant differencesLAAMToxicitySubjects
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groupsLaboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts
1993
Incubation Period of Human Immunodeficiency Virus
Alcabes P, Muñoz A, Vlahov D, Friedland G. Incubation Period of Human Immunodeficiency Virus. Epidemiologic Reviews 1993, 15: 303-318. PMID: 8174659, DOI: 10.1093/oxfordjournals.epirev.a036122.Peer-Reviewed Original Research
1990
Additional evidence for lack of transmission of HIV infection by close interpersonal (casual) contact
Friedland G, Kahl P, Saltzman B, Rogers M, Feiner C, Mayers M, Schable C, Klein R. Additional evidence for lack of transmission of HIV infection by close interpersonal (casual) contact. AIDS 1990, 4: 639-644. PMID: 2118767, DOI: 10.1097/00002030-199007000-00005.Peer-Reviewed Original ResearchConceptsHousehold contactsHIV infectionAIDS patientsClose interpersonal contactNon-sexual contactsPossibility of transmissionAdult patientsHIV antibodiesMedian durationMedian timeP24 antigenHIV transmissionPhysical examinationSerum antibodiesPatientsLast contactLack of transmissionLast evaluationInitial evaluationMonthsInfectionHIVSymptomsAntigenAIDS
1988
Fever in hospitalized medical patients
Bor D, Makadon H, Friedland G, Dasse P, Komaroff A, Aronson M. Fever in hospitalized medical patients. Journal Of General Internal Medicine 1988, 3: 119-125. PMID: 3357068, DOI: 10.1007/bf02596115.Peer-Reviewed Original ResearchConceptsHospitalized medical patientsBacterial infectionsFever episodesMedical patientsSubsequent fever episodesAverage hospital stayCause of feverLength of hospitalizationUrinary tract infectionOccurrence of feverLower febrile responsesAfebrile patientsFebrile daysHospital stayHospital daysOlder patientsTract infectionsYounger patientsClinical profileFebrile patientsClinical cluesDrug reactionsMyocardial infarctionPrior infectionFebrile response
1986
Lack of Transmission of HTLV-III/LAV Infection to Household Contacts of Patients with AIDS or AIDS-Related Complex with Oral Candidiasis
Friedland G, Saltzman B, Rogers M, Kahl P, Lesser M, Mayers M, Klein R. Lack of Transmission of HTLV-III/LAV Infection to Household Contacts of Patients with AIDS or AIDS-Related Complex with Oral Candidiasis. New England Journal Of Medicine 1986, 314: 344-349. PMID: 3456076, DOI: 10.1056/nejm198602063140604.Peer-Reviewed Original ResearchConceptsHTLV-III/LAVHousehold contactsOral candidiasisHuman T-cell lymphotropic virus type III/lymphadenopathy-associated virusHTLV-III/LAV infectionType III/lymphadenopathy-associated virusNonsexual household contactsLymphadenopathy-associated virusEvidence of infectionRisk of infectionRisk of transmissionNonsexual contactImmunodeficiency syndromeAIDS patientsPhysical examinationSerum antibodiesIndex patientsPatientsLack of transmissionSexual partnersAIDSInfectionFive-year-old childrenCandidiasisSame household
1985
The Treatment of Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome
Small C, Harris C, Friedland G, Klein R. The Treatment of Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome. JAMA Internal Medicine 1985, 145: 837-840. PMID: 3873229, DOI: 10.1001/archinte.1985.00360050081015.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaImmunodeficiency syndromeAdverse reactionsCarinii pneumoniaEpisodes of PCPRecurrent Pneumocystis carinii pneumoniaAcquired Immunodeficiency SyndromeUnresponsive infectionsLate recurrenceTrimethoprim-sulfamethoxazolePatientsAdditional episodesSyndromeTherapySecond weekPneumoniaEpisodesImmediate reactionsFailure rateLeukopeniaRashFeverRecurrenceHepatotoxicityInfection
1978
Pyrogen Reactions Associated with the Infusion of Normal Serum Albumin (Human)
Steere A, Rifaat M, Seligmann E, Hochstein H, Friedland G, Dasse P, Wustrack K, Axnick K, Barker L. Pyrogen Reactions Associated with the Infusion of Normal Serum Albumin (Human). Transfusion 1978, 18: 102-107. PMID: 625774, DOI: 10.1046/j.1537-2995.1978.18178118551.x.Peer-Reviewed Original ResearchConceptsNormal serum albuminEndotoxin concentrationsPyrogen reactionsLimulus testAlbumin infusionHospital surveillanceProspective studySame physicianRecurrent reactionsSingle patientPositive testPatientsLimulus amebocyte lysate testInfusionLimulus assaySerum albuminRabbit pyrogen testLysate testMedian concentrationsAlbuminPyrogen testSuspect reactions